Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug


10 June 2021 - A third member of a key FDA advisory panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.

Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said the agency's decision on Biogen "was probably the worst drug approval decision in recent U.S. history," according to his resignation letter obtained by CNBC.

Read CNBC News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation